Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting ...Middle East

ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent presents phase 1 clinical data of ibi351 krasg12c inhibitor as monotherapy for metastatic colorectal cancer at the 2023 asco annual meeting was published today ( Tuesday 06/06/2023 - 03:09 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting )

Also on site :

• Another Weight Loss Surgery and a Wedding Bombshell: Spoilers From '1000-Lb Sisters' Season 8 Episode 2
• Trump-Iran latest: President threatens ‘very strong action’ if protesters are hanged after forced confessions
• Saks Global Secures $1.75 Billion of Committed Capital and Announces Return of Industry Veterans to Advance Transformation of Iconic Luxury Portfolio